HYTRIN
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYTRIN (terazosin) is an oral alpha-1 adrenergic receptor antagonist approved in 1994 for benign prostatic hyperplasia (BPH). It works by blocking alpha-1 receptors in the prostate and bladder neck, relaxing smooth muscle and improving urinary flow. The drug is indicated specifically for symptomatic BPH in men experiencing urinary hesitancy, frequency, nocturia, and weak stream.
LOE Approaching
As a legacy asset approaching loss of exclusivity, HYTRIN is transitioning to maintenance/decline mode with limited team expansion opportunities and focus on generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Started Aug 1998
1,993 enrolled
Prostatic Hyperplasia
Career Relevance
Working on HYTRIN offers limited career growth in a declining brand with approaching LOE and mature market saturation. Roles are primarily defensive—managing generic transition, maintaining clinical relationships, and optimizing pricing—rather than driving expansion or innovation.
Brand Manager
Worked on HYTRIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.